ReviewCurrent opinion in infectious diseases2020
Subarachnoid neurocysticercosis: emerging concepts and treatment.
Review in Current opinion in infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00001205 (Natural History of Treated Neurocysticercosis and Long-Term Outcomes), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Neuroimaging Features of an Experimental Model of Extraparenchymal Neurocysticercosis.Acta parasitologica · 2026Article
- Subarachnoid neurocysticercosis in a rural area of the Bolivian Chaco: A population-based survey through the use of a novel urine antigen assay.PLoS neglected tropical diseases · 2026Article
- Eosinophil recruitment and activation in the central nervous system of patients with subarachnoid neurocysticercosis.Journal of neuroinflammation · 2025Article
- Calcified Neurocysticercosis: Understanding Dead (Not Necessarily Inactive) Parasites.The American journal of tropical medicine and hygiene · 2025Review
- Molecular Mimicry Drives Locally Produced Autoantibodies in Subarachnoid Neurocysticercosis.Open forum infectious diseases · 2025Article
- Repair capacity ofFuture microbiology · 2025Article
- Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10-Producing Cell Populations During Treatment.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Murine Extraparenchymal Neurocysticercosis: Appropriate Model for Evaluating Anthelminthic and Anti-Inflammatory Treatment Schedules.Tropical medicine and infectious disease · 2024Article
- Transcriptomic analysis of subarachnoid cysts of Taenia solium reveals mechanisms for uncontrolled proliferation and adaptations to the microenvironment.Scientific reports · 2024Article
- Next-generation sequencing of cerebrospinal fluid for the diagnosis and monitoring of neurocysticercosis.Acta neurologica Belgica · 2024Article
- Silent Intruder: Unusual Presentation of Neurocysticercosis in an HIV-Infected Patient from the Far Northern Brazilian Amazon.Medicina (Kaunas, Lithuania) · 2024Article
- Current Role of Surgery in the Treatment of Neurocysticercosis.Pathogens (Basel, Switzerland) · 2024Review
- Beyond the acute phase: a comprehensive literature review of long-term sequelae resulting from infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?Pathogens (Basel, Switzerland) · 2023Article
- Older Age in Subarachnoid Neurocysticercosis Reflects a Long Prepatent Period.The American journal of tropical medicine and hygiene · 2023Article
- Article
- Spinal Arachnoiditis in Patients with Coccidioidomycosis Meningitis-Analysis of Clinical and Imaging Features.Journal of fungi (Basel, Switzerland) · 2022Article
- High-resolution vessel wall magnetic resonance imaging for the diagnosis of neurocysticercosis vasculitis.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Spinal arachnoiditis and syringomyelia: Review of literature with emphasis on postinfectious inflammation and treatment.Surgical neurology international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewSubarachnoid neurocysticercosis (SUBNCC) is caused by a morphologically unique proliferative form of Taenia solium involving the subarachnoid spaces. Prolonged therapy based upon the pathophysiology of SUBNCC and long-term follow-up have shed light on the course of disease and led to highly improved outcomes. RECENT
findingsSUBNCC has a prolonged incubation period of between 10 and 25 years characterized by cyst proliferation and growth and invasion of contiguous spaces leading to mass effect (Stage 1). With induction of the host-immune responses, cysts degenerate leading to a predominately inflammatory arachnoiditis (Stage 2) causing hydrocephalus, infarcts, and other inflammatory based neurological manifestations. Inactive disease (Stage 3) may occur naturally but mostly is a result of successful treatment, which generally requires prolonged intensive anthelminthic and antiinflammatory treatments. Cerebral spinal fluid cestode antigen or cestode DNA falling to nondetectable levels predicts effective treatment. Prolonged treatment with extended follow-up has resulted in moderate disability and no mortality. Repeated short intensive 8-14-day courses of treatment are also used, but long-term outcomes and safety using this strategy are not reported. SUMMARY: SUBNCC gives rise to a chronic arachnoiditis. Its unique ability to proliferate and induce inflammatory responses requires long-term anthelmintic and antiinflammatory medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.